Loading…
← CockpitCompetitor Analysis › DRAGARWQ.NS Dr. Agarwal'S Eye Hospital LimitedOpen in the cockpit ↗

Dr. Agarwal'S Eye Hospital LimitedDRAGARWQ.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Medical/Nursing Services
Momentum leader 81
Mkt cap
$292M
US dollars, full cap
Free float
19%
of shares outstanding
$/day
$88,337
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+11.5 pp
WACC 11.1%
Hurdle
-8 pp
Req g minus delivered
Close · INR₹5,834
1Dn/a
1W+5.1%
1M+14.9%
3M+10.2%
6M+14.2%
YTDn/a
1Yn/a
ATR %3.4%
52w lowhigh5.7% off high

What Dr. Agarwal'S Eye Hospital does

Employees: 1,356

Dr. Agarwal'S Eye Hospital at a glance

Size Dr. Agarwal'S Eye Hospital (DRAGARWQ.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $292M, the 1066th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹5,834 on 18 Nov 2026.

Performance Over six months the shares gained 14.2%, against -4.0% for the median peer and +3.8% for the India market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 20.0% over the last twelve months (peer median +5.1%); the operating margin is 21.1% (peer median 8.0%).

Valuation It trades at 5.5× enterprise value to sales against a peer median of 1.5× (4th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.5 points above its cost of capital (11.1% WACC).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026DRAGARWQ.NS 114Peer median 96
Six months, rebased to 100: Dr. Agarwal'S Eye Hospital against the median of its 20 peers (local-currency closes).

Dr. Agarwal'S Eye Hospital financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹4.97B₹4.71B₹3.97B₹3.19B₹2.68B
Revenue growth—+19%+24%+19%—
Gross profit₹1.82B₹1.61B₹1.27B₹1.03B₹898M
EBITDA₹1.51B₹1.48B₹1.21B₹931M₹766M
Net income₹762M₹701M₹546M₹464M₹369M
Free cash flown/a₹458M-₹124M₹192M-₹23.0M
Capital expendituren/a₹984M₹1.03B₹713M₹703M
Total debtn/a₹3.26B₹3.33B₹2.68B₹2.32B

Quarterly statements and history in the cockpit →

Dr. Agarwal'S Eye Hospital competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%3218AUNANIOX300642AYUPAM12JSLLIDXACLSRTA127120301060DNAWELLFLGTNEPHROPLUSGMRSDRAGARWQ.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Dr. Agarwal'S Eye Hospital is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%2×4×6×3218AUNANIOXSTLN300642AYUPAM129860JSLLIDXACL127120301060DNAWELLNEPHROPLUS1951DRAGARWQ.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dr. Agarwal'S Eye Hospital is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%3218AUNANIOXSTLN300642AYUPA9860JSLLACL301060WELLNEPHROPLUSGMRS1951DRAGARWQ.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dr. Agarwal'S Eye Hospital is the large dot.

Dr. Agarwal'S Eye Hospital competitors and peer comparison

How Dr. Agarwal'S Eye Hospital compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dr. Agarwal'S Eye Hospital against its 20 peers (data as of 18 Nov 2026)
MeasureDRAGARWQ.NSPeer medianRank in peer set
1-month return+14.9%-9.6%2nd highest of 21
6-month return+14.2%-4.0%4th highest of 20
Distance from 52-week high-5.7%-30.8%2nd highest of 21
Revenue growth (TTM)+20.0%+5.1%8th highest of 21
Operating margin21.1%8.0%4th highest of 21
EV / Sales5.5×1.5×4th most expensive of 21
Growth the price implies (Req g, 7 yrs)19.6%5.6%2nd most demanding of 17
Growth delivered (Del g)+27.5%+15.4%4th highest of 17
Hurdle (Req g minus delivered)-7.9 pp-13.8 pp7th most demanding of 17
ROIC minus cost of capital+11.5 pp-2.5 pp3rd highest of 20
EV / EBITDA18.1×8.8×2nd most expensive of 13
Net debt / EBITDA1.5×1.6×7th least indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%5.5×19.6%+27.5%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%2.4×-13.8%+15.4%
Auna AUNAUnited States$309M-5%+17%13%1.0×-10.7%+24.4%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%4.9×3.4%+15.3%
Oncology Institute STLNUnited States$326Mn/a+35%-3%0.6×5.4%+21.8%
Tellgen 300642.SZChina$328M-11%+5%8%5.2×18.8%-5.8%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%0.4×-14.9%+9.6%
M1 Kliniken M12.DEGermany$368M+1%-28%13%1.2×-5.3%+17.9%
ADICON 9860.HKHong Kong$393M+5%+1%4%1.3×12.3%-1.5%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%4.0×7.3%+42.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%1.5×7.8%+17.7%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%1.3×4.3%+2.6%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%1.4×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%25.2×n/an/a
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%2.3×5.9%+3.2%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%6.5×n/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%1.2×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%1.2×n/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%5.6×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%0.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%2.8×17.8%+12.4%

Questions

Which companies are Dr. Agarwal'S Eye Hospital's closest peers?
The cockpit's peer set: Universal Vision Biotechnology (3218.TWO), Auna (AUNA), NIOX (NIOX.L), Oncology Institute (STLN), Tellgen (300642.SZ), Australian Unity Ltd Pref (AYUPA.AX), M1 Kliniken (M12.DE), ADICON (9860.HK).
Is Dr. Agarwal'S Eye Hospital expensive compared with its peers?
On ev / sales it trades at 5.5× against a peer median of 1.5×, 4th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Dr. Agarwal'S Eye Hospital stock performed?
Over six months to 18 Nov 2026 the shares returned +14.2% against -4.0% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.